Table 2. Subject treatment characteristics by co-infection status.
| Total (n=180) | HCV mono (n=136) | HCV/HIV coinfected (n=41) | Significance | OR (95%) | |
|---|---|---|---|---|---|
|
| |||||
| First HCV treatment n (%) | 129 (72) | 97 (71) | 32 (78) | p = 0.47 | 1.4 (0.6-3.1) |
|
| |||||
| Interferon alfa-2a n (%) | 144 (80) | 104 (76) | 40 (98) | P = 0.00 | 11.2(1.5-84.6) |
|
| |||||
| HCV Genotype n (%) | |||||
| Type 1 | 127 (71) | 96 (71) | 31 (76) | ||
| Type 2 | 26 (14) | 18 (13) | 8 (20) | ||
| Type 3 | 16 (9) | 14 (10) | 2 (5) | ||
| Type 4 | 4 (2) | 4 (3) | 0 (0) | p = 0.38 | |
|
| |||||
| Self-injects IFN n (%) | 155 (86) | 121 (89) | 34 (83) | p = 0.50 | 0.7 (0.3-1.9) |
|
| |||||
| Ribavirin dose n (%) | |||||
| 800mg or < | 45 (25) | 34 (25) | 11 (27) | ||
| 1000mg | 44 (24) | 36 (26) | 8 (20) | ||
| 1200mg or > | 65 (36) | 47 (35) | 18 (44) | p = 0.52 | |
|
| |||||
| Time on treatment in weeks mean (sd) | 19.3 (13.4) | 19.2 (12.8) | 19.6 (15.5) | p = 0.88 | |
|
| |||||
| In clinical trial n (%) | 27 (15) | 22 (16) | 5 (12) | p = 0.57 | 0.7 (0.3-2.1) |
|
| |||||
| On anti-depressant n (%) | 60 (33) | 35 (26) | 25 (61) | p = 0.00 | 4.5 (2.1-9.5) |
|
| |||||
| Meds for anemia n (%) | 67 (37) | 46 (34) | 21 (51) | p = 0.53 | 2.0 (1.0-4.1) |
|
| |||||
| Mood mean (sd) | 6.4 (2.2) | 6.5 (2.1) | 6.3 (2.6) | p = 0.74 | |
|
| |||||
| Energy mean (sd) | 5.4 (2.5) | 5.4 (2.5) | 5.5 (2.5) | p = 0.76 | |
|
| |||||
| Side Effects mean (sd) | 4.6 (2.6) | 4.8 (2.7) | 4.2 (2.7) | p = 0.26 | |